X Facebook LinkedIn WhatsApp Press Releases (-) Any 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2019 February 20, 2019 argenx to host conference call & webcast to report fourth quarter business update and full year 2018 financial results on February 28, 2019 February 3, 2019 argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology January 17, 2019 argenx announces closing of exclusive global collaboration and license agreement for cusatuzumab (ARGX-110) with Janssen January 2, 2019 argenx to Present at 37th Annual J.P. Morgan Healthcare Conference 2018 December 2, 2018 argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110) December 2, 2018 argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia November 6, 2018 argenx to Present at Upcoming Investor Conferences October 31, 2018 argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition October 24, 2018 argenx reports third quarter 2018 financial results and provides business update October 8, 2018 argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology September 20, 2018 argenx announces closing of U.S. public offering September 18, 2018 argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering Pagination First page « First Previous page ‹ Previous … Page 12 Page 13 Page 14 Page 15 Current page 16 Page 17 Page 18 Page 19 Page 20 … Next page Next › Last page Last »